Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

6GK0

HUMAN DIHYDROOROTATE DEHYDROGENASE IN COMPLEX WITH CLASS III HISTONE DEACETYLASE INHIBITOR

Summary for 6GK0
Entry DOI10.2210/pdb6gk0/pdb
DescriptorDihydroorotate dehydrogenase (quinone), mitochondrial, FLAVIN MONONUCLEOTIDE, (4S)-2,6-DIOXOHEXAHYDROPYRIMIDINE-4-CARBOXYLIC ACID, ... (10 entities in total)
Functional Keywordsdehydrogenase dhodh tumor-killing drug development, antitumor protein
Biological sourceHomo sapiens (Human)
Total number of polymer chains1
Total formula weight41975.04
Authors
Hakansson, M.,Ladds, M.J.G.W.,Walse, B.,Lain, S. (deposition date: 2018-05-17, release date: 2019-11-27, Last modification date: 2024-05-15)
Primary citationLadds, M.J.G.W.,Popova, G.,Pastor-Fernandez, A.,Kannan, S.,van Leeuwen, I.M.M.,Hakansson, M.,Walse, B.,Tholander, F.,Bhatia, R.,Verma, C.S.,Lane, D.P.,Lain, S.
Exploitation of dihydroorotate dehydrogenase (DHODH) and p53 activation as therapeutic targets: A case study in polypharmacology.
J.Biol.Chem., 295:17935-17949, 2020
Cited by
PubMed Abstract: The tenovins are a frequently studied class of compounds capable of inhibiting sirtuin activity, which is thought to result in increased acetylation and protection of the tumor suppressor p53 from degradation. However, as we and other laboratories have shown previously, certain tenovins are also capable of inhibiting autophagic flux, demonstrating the ability of these compounds to engage with more than one target. In this study, we present two additional mechanisms by which tenovins are able to activate p53 and kill tumor cells in culture. These mechanisms are the inhibition of a key enzyme of the pyrimidine synthesis pathway, dihydroorotate dehydrogenase (DHODH), and the blockage of uridine transport into cells. These findings hold a 3-fold significance: first, we demonstrate that tenovins, and perhaps other compounds that activate p53, may activate p53 by more than one mechanism; second, that work previously conducted with certain tenovins as SirT1 inhibitors should additionally be viewed through the lens of DHODH inhibition as this is a major contributor to the mechanism of action of the most widely used tenovins; and finally, that small changes in the structure of a small molecule can lead to a dramatic change in the target profile of the molecule even when the phenotypic readout remains static.
PubMed: 32900849
DOI: 10.1074/jbc.RA119.012056
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (1.85 Å)
Structure validation

227561

PDB entries from 2024-11-20

PDB statisticsPDBj update infoContact PDBjnumon